Preventing relapse after stem cell transplant in high-risk leukemia or MDS
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether two drugs, Selinexor and Venetoclax, can help prevent leukemia or MDS from coming back after a stem cell transplant. It is for people who are at high risk of relapse and have recently had a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk AML or intermediate-high/high/very-high risk MDS.
- You are between 18 and 75 years old.
- You received a stem cell transplant from a matched donor about 90 to 120 days ago, and tests show the donor cells are fully working.
- You are generally able to do daily activities on your own (ECOG score 0-2).
- Your blood counts, liver, kidney, and heart function are within safe limits.
- You have no signs of cancer relapse or minimal residual disease (MRD) after transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
This trial tests a combination of two drugs (venetoclax and azacitidine) followed by a stem cell transplant from a donor for patients with a specific type of acute myeloid leukemia (AML) that has low bone marrow cell count or has developed from a prior blood disorder. The goal is to control the disease and give you a chance at a cure through transplantation.
This trial is for people age 55 and older with high-risk acute myeloid leukemia (AML) who have already had a stem cell transplant. It tests a new combination of two drugs, Selinexor and Melphalan, given twice a week to help prevent the leukemia from coming back.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.